Nasdaq Welcomes Denali Therapeutics, Inc. (NASDAQ: DNLI) to The Nasdaq Stock Market
December 08 2017 - 1:21PM
Denali Therapeutics Inc. (Nasdaq:DNLI), a biopharmaceutical company
focused on the discovery and development of therapies for patients
with neurodegenerative disease, visited the Nasdaq MarketSite in
Times Square today in celebration of its initial public offering
(IPO) on The Nasdaq Stock Market.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/9f884ad2-04de-4bbe-a467-faad9d522506
Denali Therapeutics is committed to developing therapies for
neurodegeneration, one of the most significant unmet medical needs
of our time. Denali Therapeutics relies on its core principles of
identifying and selecting targets based on validated genetic
drivers of neurodegeneration, developing medicines that effectively
cross the blood-brain barrier and target the brain, and developing
and using biomarkers for better patient selection and demonstration
of target and pathway engagement of their product candidates in
order to succeed in a field that has seen limited progress in the
past several decades.
“Neurodegenerative diseases represent one of the most
significant medical challenges facing us today, impacting millions
of people including our own families and friends. Our goal is to
defeat degeneration,” said Ryan J. Watts, Ph.D. co-founder and CEO
of Denali Therapeutics. “We are grateful for the investors who have
joined us on this journey and share our vision that the science is
breaking open, and the time is right to discover and develop
effective medicines for patients.”
“With a team of experienced and passionately dedicated
scientists and drug developers, Denali Therapeutics is committed to
developing innovative therapies for a field with severely unmet
medical needs,” said Nelson Griggs, President of the Nasdaq Stock
Exchange. “As the largest capital raise by a biotechnology company
since June 2015 as well as largest raise in healthcare deals in
2017, we are proud to welcome Denali Therapeutics to our family of
the world’s most prestigious companies as they continue to make
strides in the neurodegeneration field.”
The information contained above is provided for informational
and educational purposes only, and nothing contained herein should
be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Information about the
company is provided by the company or comes from the company’s
public filings and is not independently verified by Nasdaq. Neither
Nasdaq nor any of its affiliates makes any recommendation to buy or
sell any security or any representation about the financial
condition of any company. Statements regarding Nasdaq-listed
companies are not guarantees of future performance. Actual results
may differ materially from those expressed or implied. Past
performance is not indicative of future results. Investors should
undertake their own due diligence and carefully evaluate companies
before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY
ADVISED.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today’s global capital markets. As the creator of the world’s first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world’s securities
transactions. Nasdaq is home to approximately 3,900 total listings
with a market value of approximately $12 trillion. To learn more,
visit: http://business.nasdaq.com
|
|
|
MEDIA RELATIONS
CONTACT:
- Stephanie Lowenthal
- (646) 441-5073
- Stephanie.Lowenthal@nasdaq.com
|
- Emily Pan
- (646) 441-5120
- emily.pan@nasdaq.com
|
|
|
|
|
- NDAQG -
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024